Incyte Corp. closed 18.70% short of its 52-week high of $83.95, which the company achieved on November 8th.

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Sun Pharmaceutical Industries said that it has launched hair-loss treatment drug LEQSELVI (deuruxolitinib) in the U.S.

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

Shares of Sun Pharma rose 2 percent to Rs 1,711 in morning trade on July 15, extending their gains for a third straight ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due t ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...